Brief: Cornerstone Pharmaceuticals Initiates Phase 1 Trial Of CPI-613 In Combination With Chemoradiation For Treatment Of Advanced Pancreatic Cancer

Rafael Holdings

28/09/2022 12:15

Sept 28 (Reuters) - Rafael Holdings Inc  RFL.N :
    * CORNERSTONE PHARMACEUTICALS INITIATES PHASE 1 TRIAL OF
CPI-613®
(DEVIMISTAT) IN COMBINATION WITH CHEMORADIATION FOR THE
TREATMENT OF ADVANCED PANCREATIC CANCER
    * RAFAEL HOLDINGS - FDA & EMA HAS GRANTED AN ORPHAN DRUG
DESIGNATION FOR DEVIMISTAT IN PANCREATIC CANCER
    * CORNERSTONE PHARMACEUTICALS INITIATES PHASE 1 TRIAL OF
CPI-613®
(DEVIMISTAT) IN COMBINATION WITH CHEMORADIATION FOR THE
TREATMENT OF ADVANCED PANCREATIC CANCER

Source text for Eikon:  ID:nGNX7BBr06 
Further company coverage:  RFL.N 
 ((Reuters.Briefs@thomsonreuters.com;))